Alane P. Barnes, Chief Legal Officer at BioCryst Pharmaceuticals Inc., completed a pair of linked transactions on March 16, 2026, that included an option exercise and a contemporaneous sale of common stock.
On that date Barnes exercised options to acquire 150,000 shares of BioCryst common stock at an exercise price of $5.51 per share, for a total exercise cost of $826,500. The same day, she sold 150,000 shares of company stock for aggregate proceeds of $1,372,500. The sales were executed at a weighted average price of $9.15 per share, with the individual trade prices reported in the range of $8.95 to $9.57.
After these transactions, Barnes is reported to directly own 400,703 shares of BioCryst common stock.
The option grant that allowed Barnes to acquire the 150,000 shares became exercisable in installments - 25% on each of the first, second, third, and fourth anniversaries of the grant date.
According to the filing, the sales were made under a plan the reporting person adopted on August 13, 2025, pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The filing states the transactions were automatic under that plan and did not represent discretionary trades by the reporting person.
The filing also clarifies that the price shown is a weighted average and that the shares were sold in multiple transactions across the $8.95 to $9.57 range. The reporting person indicated they will provide detailed information about the number of shares sold at each price within that range to the issuer, any security holder of the issuer, or SEC staff upon request.
Market context included in the filing notes the stock was trading near $9.16 and had risen more than 8% over the prior week.
Separately, the company reported strong fourth-quarter 2025 financial results. BioCryst posted earnings per share of $1.12 for the quarter, well ahead of the consensus forecast of $0.04, reflecting what was characterized as a 2,700% surprise. Revenue for the quarter totaled $406.55 million, outstripping estimates of $150.06 million by approximately 170.92%.
Product-level results showed Orladeyo generated $151 million in revenue during the fourth quarter, a 3% increase from the preceding quarter.
Financial analysis referenced in the filing included an InvestingPro view that the shares remain undervalued at current levels. That analysis highlighted an EXCELLENT financial health score for the company, a price-to-earnings ratio of 7.48, and the company’s profitability over the trailing twelve months. The filing noted that more detailed analysis is available through BioCryst’s Pro Research Report on that platform.
In coverage reactions referenced in the filing, TD Cowen is said to have reiterated a Buy rating on BioCryst shares, maintaining a $30.00 price target and citing Orladeyo’s revenue performance and growth outlook as key drivers.
Taken together, the insider transaction and the company’s fourth-quarter results were presented in the filing as indicators of the company’s current financial position and market reception. The filing preserves that the sales were conducted under a pre-existing, automatic plan and that further details about execution prices are available upon request.
Key points
- Barnes exercised 150,000 options at $5.51 per share and sold 150,000 shares on March 16, 2026; sale proceeds totaled $1,372,500 and the exercise cost totaled $826,500.
- Following the transactions, Barnes directly owns 400,703 shares; the sale was executed under a Rule 10b5-1 plan adopted August 13, 2025 and was automatic rather than discretionary.
- BioCryst reported strong fourth-quarter 2025 results: EPS $1.12 versus $0.04 expected, revenue $406.55 million versus $150.06 million expected, and Orladeyo revenue of $151 million (up 3% sequentially).
Risks and uncertainties
- The filing indicates the sale occurred under an automatic 10b5-1 plan, which may limit interpretation of the insider sale as a discretionary signal about company prospects - this affects investor assessment in the pharmaceuticals sector and equity markets.
- The filing notes the weighted average price and a range for executed trades; exact quantities sold at each specific price point are not provided in the document and would require additional disclosure upon request, creating short-term transparency limits for market participants.
- While the company reported strong quarterly results, the filing itself does not project future performance; reliance on one quarter’s results introduces uncertainty for valuation and investment decisions in healthcare and biotech equities.